Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 1689-1696

  Spina, Annamaria ^a   Sorvillo, Luca ^a   Chiosi, Emilio ^a   Esposito, Antonietta ^a   Di Maiolo, Francesca ^a   Sapio, Luigi ^a   Caraglia, Michele ^a   Naviglio, Silvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Chemosensitivity; Combination antitumor therapy; Cytotoxicity; Inorganic phosphate; Osteosarcoma cells

Indexed keywords

DOXORUBICIN; FLUOROURACIL; PACLITAXEL; PHOSPHATE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MONOTHERAPY; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SYNERGISM; FLUOROURACIL; HUMANS; OSTEOSARCOMA; PACLITAXEL; PHOSPHATES;

EID: 84876264669     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2306     Document Type: Article

References (42)

1. Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10: 315-327, 2008.
2. Dai X, Ma W, He X and Jha RK: Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit 17: 177-190, 2011.
3. Kim SY and Helman LJ: Strategies to explore new approaches in the investigation and treatment of osteosarcoma. Cancer Treat Res 152: 517-528, 2009.
4. Hattinger CM, Pasello M, Ferrari S, Picci P and Serra M: Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15: 615-634, 2010.
5. Gutierrez ME, Kummar S and Giaccone G: Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 6: 259-265, 2009.
6. Raina K and Agarwal R: Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin 28: 1466-1475, 2007. (Pubitemid 47366688)
7. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B and Jäger W: Chemopreventive effects of resveratrol and resveratrol derivatives. Ann NY Acad Sci 1215: 89-95, 2011.
8. Tian L, Yin D, Ren Y, Gong C, Chen A and Guo FJ: Plumbagin induces apoptosis via the p53 pathway and generation of reactive oxygen species in human osteosarcoma cells. Mol Med Rep 5: 126-132, 2012.
9. Wu CL, Huang AC, Yang JS, et al: Benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC)-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of caspase-3, mitochondria dysfunction and nitric oxide (NO) in human osteogenic sarcoma U-2 OS cells. J Orthop Res 29: 1199-1209, 2011.
10. Maran A, Shogren KL, Benedikt M, Sarkar G, Turner RT and Yaszemski MJ: 2-Methoxyestradiol-induced cell death in osteo sarcoma cells is preceded by cell cycle arrest. J Cell Biochem 104: 1937-1945, 2008.
11. Chen JT, Fong YC, Li TM, et al: DDTD, an isoflavone derivative, induces cell apoptosis through the reactive oxygen species/apoptosis signal-regulating kinase 1 pathway in human osteo sarcoma cells. Eur J Pharmacol 597: 19-26, 2008.
12. Yoshiko Y, Candeliere GA, Maeda N and Aubin JE: Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization. Mol Cell Biol 27: 4465-4474, 2007. (Pubitemid 46906569)
13. Takeda E, Taketani Y, Sawada N, Sato T and Yamamoto H: The regulation and function of phosphate in the human body. Biofactors 21: 345-355, 2004. (Pubitemid 40921881)
14. Prié D, Beck L, Urena P and Friedlander G: Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 14: 318-324, 2005. (Pubitemid 40863067)
15. Khoshniat S, Bourgine A, Julien M, Weiss P, Guicheux J and Beck L: The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals. Cell Mol Life Sci 68: 205-218, 2011.
16. Naviglio S, Spina A, Chiosi E, et al: Inorganic phosphate inhibits growth of human osteosarcoma U2OS cells via adenylate cyclase/cAMP pathway. J Cell Biochem 98: 1584-1596, 2006. (Pubitemid 44141862)
17. Naviglio S, Di Gesto D, Borrelli V, et al: Novel molecular mechanisms by inorganic phosphate in osteosarcoma U2OS cells. Front Biosci 3: 1249-1258, 2011.
18. Spina A, Sorvillo L, Di Maiolo F, et al: Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway. J Cell Physiol 228: 198-206, 2013.
19. Camalier CE, Young MR, Bobe G, Perella CM, Colburn NH and Beck GR Jr: Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis. Cancer Prev Res 3: 359-370, 2010.
20. Zou J, Gan M, Mao N, Zhu X, Shi Q and Yang H: Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by down regulating survivin. Arch Med Res 41: 162-169, 2010.
21. Olijslagers SJ, Zhang YH, Backendorf C and Noteborn MH: Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin Pharmacol Toxicol 100: 127-131, 2007. (Pubitemid 46146717)
22. Mao FJ, Sidorova JM, Lauper JM, Emond MJ and Monnat RJ: The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage. Cancer Res 70: 6548-6555, 2010.
23. Naviglio S, Di Gesto D, Romano M, et al: Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther 8: 1183-1190, 2009.
24. Naviglio S, Di Gesto D, Illiano F, et al: Leptin potentiates antiproliferative action of cAMP elevation via protein kinase A down-regulation in breast cancer cells. J Cell Physiol 225: 801-809, 2010.
25. Naviglio S, Mattecucci C, Matoskova B, et al: UBPY: a growth-regulated human ubiquitin isopeptidase. EMBO J 17: 3241-3250, 1998. (Pubitemid 28279498)
26. Lamberti M, Porto S, Marra M, et al: 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res 31: 60-68, 2012.
27. Bradford MM: A rapid and sensitive method for the quantifi cation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72: 248-254, 1976.
28. Lu KH, Lue KH, Chou MC and Chung JG: Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS). J Orthop Res 23: 988-994, 2005.
29. Zhu JJ, Li FB, Zhou JM, Liu ZC, Zhu XF and Liao WM: The tumor suppressor p33ING1b enhances taxol-induced apoptosis by p53-dependent pathway in human osteosarcoma U2OS cells. Cancer Biol Ther 4: 39-47, 2005.
30. Song B, Wang Y, Xi Y, et al: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28: 4065-4074, 2009.
31. Im YS, Shin HK, Kim HR, et al: Enhanced cytotoxicity of 5-FU by bFGF through up-regulation of uridine phosphorylase 1. Mol Cells 28: 119-124, 2009.
32. Koto K, Murata H, Kimura S, et al: Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 24: 233-239, 2010.
33. Varmeh S and Manfredi JJ: Overexpression of the dual specificity phosphatase, Cdc25C, confers sensitivity on tumor cells to doxorubicin-induced cell death. Mol Cancer Ther 7: 3789-3799, 2008.
34. Zucchini C, Bianchini M, Valvassori L, et al: Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. Bone 34: 672-679, 2004. (Pubitemid 38393803)
35. Agner J, Falck J, Lukas J and Bartek J: Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp Cell Res 302: 162-169, 2005. (Pubitemid 39550459)
36. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
37. Tentner AR, Lee MJ, Ostheimer GJ, Samson LD, Lauffenburger DA and Yaffe MB: Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol Syst Biol 31: 1-18, 2012.
38. Yuan XW, Zhu XF, Huang XF, et al: Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacol Sin 28: 1835-1841, 2007.
39. Chiosi E, Spina A, Sorrentino A, et al: Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death. J Interferon Cytokine Res 27: 589-597, 2007. (Pubitemid 47122718)
40. Zhao P and Astruc D: Docetaxel nanotechnology in anticancer therapy. Chem Med Chem 7: 952-972, 2012.
41. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
42. Lopez-Heredia MA, Kamphuis GJ, Thüne PC, Öner FC, Jansen JA and Walboomers XF: An injectable calcium phosphate cement for the local delivery of paclitaxel to bone. Biomaterials 32: 5411-5416, 2011.